一个可解释的基于机器学习的阿尔茨海默病预测模型在中国纵向老龄化研究研究
Ling Yue1, Wu-Gang Chen2, Sai-Chao Liu2
1The Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frontiers in aging neuroscience
|November 29, 2023
概括
这项研究开发了一种可解释的AI模型,用于使用生活方式和医疗数据预测阿尔茨海默病 (AD) 和轻度认知障碍 (MCI),实现早期诊断和干预的高准确性.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,需要早期诊断才能有效管理.
- 轻度认知障碍 (MCI) 是阿尔茨海默病的前期阶段,强调需要准确的预测.
- 中国纵向衰老研究 (CLAS) 为研究AD和MCI预测提供了有价值的数据集.
研究的目的:
- 开发和验证阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的可解释预测模型.
- 确定生活方式和病史中的关键特征,这些特征有助于AD/MCI预测.
- 通过计算机辅助诊断系统来增强临床决策.
主要方法:
- 在CLAS数据上使用集体学习和特征选择技术 (n=3,514).
- 应用并比较了9个机器学习分类器和5个特征选择方法.
- 采用了SHapley添加式解释 (SHAP) 算法来实现模型的可解释性.
主要成果:
- 实现了MCI (89.2%) 和AD (99.2%) 的高预测准确度.
- 在MCI和AD预测方面表现出极好的灵敏度和特异性.
- 确定了影响认知功能的重要生活方式和病史因素.
结论:
- 开发的可解释人工智能模型准确预测AD和MCI,为贡献因素提供了有价值的见解.
- 该模型的可解释性有助于理解生活方式,健康史和认知衰退之间的关系.
- 这种方法在AD和MCI的计算机辅助诊断系统中具有很大的临床应用潜力.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
